health - "develop"

A formula has been developed to assign utility values to quality of life profiles described by the English and Chinese versions of the Functional Assessment of Cancer Therapy-General (FACT-G), which is a commonly used questionnaire in cancer care and research. While there are many useful questionnaires to describe a cancer patient's quality of life, most of them do not quantify the health utility value of that quality of life situation, a requirement for cost-utility analysis.

A comprehensive software package designed to significantly improve the quality and accessibility of nuclear cardiology images has been licensed by Emory University to Syntermed, an Atlanta-based nuclear medicine imaging and informatics software company. The software, called the Emory Reconstruction ToolboxT (ERTbT), was developed by Emory medical scientists Ernest Garcia, PhD, and Ji Chen, PhD, and their colleagues through a grant from the Georgia Research Alliance (GRA).

Neurons constituting the optic nerve wire up to the brain in a highly dynamic way. Cell bodies in the developing retina sprout processes, called axons, which extend toward visual centers in the brain, lured by attractive cues and making U-turns when they take the wrong path. How they find targets so accurately is a central question of neuroscience today. Using the mouse visual system, a team of Salk Institute for Biological Studies investigators led by Dennis O'Leary, Ph.D.

Thanks to a newly-developed technology at the Delft University of Technology in the Netherlands, global shortages of radio isotopes for cancer diagnosis could be a thing of the past. This is the message from Prof. Bert Wolterbeek of Delft University of Technology's Reactor Institute Delft (RID) in an article in university journal Delta.

Rush University Medical Center will be launching the first systematic newborn screening program for the genetic mutation that results in fragile X syndrome - the single most common known genetic cause of autism and mental retardation. For the first time, a blood test has been developed that can identify the fragile X mutation using small drops of blood collected from infants after birth. The test developed by researchers at UC Davis in Sacramento Calif.